Nang Kuang Pharmaceutical Co., Ltd. (TPE:1752)
39.45
-0.55 (-1.38%)
Sep 9, 2025, 1:35 PM CST
Nang Kuang Pharmaceutical Revenue
Nang Kuang Pharmaceutical had revenue of 541.71M TWD in the quarter ending June 30, 2025, with 5.74% growth. This brings the company's revenue in the last twelve months to 2.28B, up 8.89% year-over-year. In the year 2024, Nang Kuang Pharmaceutical had annual revenue of 2.20B with 2.31% growth.
Revenue (ttm)
2.28B
Revenue Growth
+8.89%
P/S Ratio
1.77
Revenue / Employee
4.13M
Employees
552
Market Cap
4.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.20B | 49.63M | 2.31% |
Dec 31, 2023 | 2.15B | 209.74M | 10.81% |
Dec 31, 2022 | 1.94B | 160.39M | 9.01% |
Dec 31, 2021 | 1.78B | 25.27M | 1.44% |
Dec 31, 2020 | 1.75B | -7.43M | -0.42% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Caliway Biopharmaceuticals | 44.83M |
PharmaEssentia | 12.63B |
Bora Pharmaceuticals Co., LTD. | 21.32B |
Lotus Pharmaceutical | 19.12B |
Lumosa Therapeutics | 37.25M |
Oneness Biotech | 112.57M |
Polaris Group | 64.02M |
Pell Bio-Med Technology | 27.43M |